Remix CSO Dominic Reynolds and CEO Peter Smith exemplify each and every one of our core values as they take on the White Mountains with the Atlas Venture group for their second time! 🏔 We love to see Remix leadership pushing the limits and strengthening connections in and out of the office! #CourageousCuriosity #TrueToOurRNA #RemixingTogether
Remix Therapeutics
Biotechnology Research
Watertown, MA, MA 6,463 followers
Reprogramming RNA Processing, Designing Therapeutic Solutions
About us
Remix launched in 2020 with a vision to transform patient's lives through modulation of RNA processing. Our breakthrough science provides a path to identify small molecules that impact the expression of disease driving mRNAs and proteins. We take on the challenge of addressing drug targets in diseases of high unmet medical need to bring new therapeutic options to patients. Remix has a commitment to demonstrate the highest levels of scientific integrity with urgency because those patients are counting on us to deliver. With an in-house technology platform built from scratch, we have rapidly generated multiple drug discovery programs that are advancing towards the clinic.
- Website
-
https://www.remixtx.com
External link for Remix Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Watertown, MA, MA
- Type
- Privately Held
- Founded
- 2018
Locations
-
Primary
100 Forge Rd
Watertown, MA, MA 02472, US
Employees at Remix Therapeutics
Updates
-
Looking forward to hearing CEO Peter Smith share the latest company updates at the 2024 RBC Capital Markets Biotechnology Private Company Virtual Conference later this afternoon!
-
#Kudos to Sarah Sirin, Remix Director of Computational Chemistry, who was an industry panelist at the IMMERSE Symposium for Introducing Molecular Modeling Experiences to Underrepresented Students last Friday! IMMERSE, a National Science Foundation (NSF) initiative, provides students with valuable #STEM experience and skills. We love to see #Remixers supporting diversity in the life sciences! 🔬 🖥
-
We’re excited to announce that Remix SVP of Translational Medicine & Data Sciences, Silvia Buonamici will be sharing insights on REM-422, a potent and selective MYB mRNA degrader to target MYB-driven hematological and solid cancers at the RNA Therapeutics Symposium 2024 in Portugal on September 25th. This further supports our commitment to transforming treatment landscapes through innovative RNA processing therapies. Full program here: https://bit.ly/4ezb5BP #RemixTherapeutics #RNATherapeutics #RNATherapeuticsSymposium2024 #RNAHorizons
-
#Remixers came together this week to assemble hundreds of mentoring kits for the next semester of young scientists with Science Club for Girls. 🔬 👩🔬 Special thanks to Adina Chasan-Taber for sharing some powerful stats on the program’s amazing success. 🙌 We're proud to support their mission!
-
Remix CEO Peter Smith and CFO Rob Gagnon are pleased to be hosting investor meetings at the Cantor Fitzgerald Global Healthcare conference tomorrow in New York.
-
🏃♂️Excited to cheer on our CEO, Peter Smith, as he joins the Atlas Venture group once again in the RAGNAR Reach the Beach run this weekend! 🏅 🏔️ We're so proud to see our leadership taking on new challenges and raising money for good causes. Good luck to all the runners! #RTB2024
-
Our CEO, Peter Smith, will be participating in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference in NYC tomorrow, sharing updates on how Remix is developing novel therapies by modulating RNA processing with small molecules.
-
Remix will be attending several investor conferences in September in NY! Read the press release here: https://bit.ly/3Z20BX9